Safety and efficacy of image‑guided enzyme‑targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer

Nishioka,Akihito; Ogawa,Yasuhiro; Miyatake,Kana; Tadokoro,Michiko; Nogami,Munenobu; Hamada,Norihiko; Kubota,Kei; Kariya,Shinnji; Kohsaki,Takuhiro; Saibara,Toshiji; Okabayashi,Takehiro; Hanazaki,Kazuhiro

doi:10.3892/ol.2014.2101

Safety and efficacy of image‑guided enzyme‑targeting radiosensitization and intraoperative radiotherapy for locally advanced unresectable pancreatic cancer

Authors:
- Akihito Nishioka
- Yasuhiro Ogawa
- Kana Miyatake
- Michiko Tadokoro
- Munenobu Nogami
- Norihiko Hamada
- Kei Kubota
- Shinnji Kariya
- Takuhiro Kohsaki
- Toshiji Saibara
- Takehiro Okabayashi
- Kazuhiro Hanazaki
View Affiliations

Affiliations: Department of Diagnostic Radiology and Radiation Oncology, Kochi University School of Medicine, Kohasu, Okoh‑cho, Nankoku‑shi, Kochi 783‑8505, Japan, Department of First Internal Medicine, Kochi University School of Medicine, Kohasu, Okoh‑cho, Nankoku‑shi, Kochi 783‑8505, Japan, Department of First Surgery, Kochi University School of Medicine, Kohasu, Okoh‑cho, Nankoku‑shi, Kochi 783‑8505, Japan
Published online on: April 28, 2014 https://doi.org/10.3892/ol.2014.2101
Pages: 404-408

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A novel radiosensitization treatment involving the injection of hydrogen peroxide and sodium hyaluronate, using ultrasonic guidance, into a tumor immediately prior to intraoperative radiotherapy (IORT) was established for patients with stage IVa locally advanced unresectable pancreatic cancer. The aim of the present study was to assess the safety and efficacy of this novel treatment, termed Kochi Oxydol‑Radiation Therapy for Unresectable Carcinomas‑IORT (KORTUC and IORT). In total, 12 patients were treated with KORTUC‑IORT, external‑beam radiotherapy and systemic chemotherapy using gemcitabine hydrochloride and S‑1. For evaluation of the therapeutic and adverse effects, contrast‑enhanced computed tomography was conducted prior to the treatment, and one and six months following KORTUC‑IORT. Medical examinations were performed every month at the regularly scheduled follow‑up visits. The one‑ and two‑year survival rates were 75 and 25%, respectively, and the median survival time was 16 months. All treatments associated with KORTUC‑IORT were well‑tolerated by the patients, with a small number of adverse effects and no serious complications. It was identified that the delivery of KORTUC‑IORT is safe and effective, in combination with external‑beam radiotherapy and systemic chemotherapy, for patients with locally advanced unresectable pancreatic cancer.

View Figures

View References

1	Ogawa Y, Takahashi T, Kobayashi T, et al: Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against irradiation. Int J Mol Med. 12:453–458. 2003.
2	Ogawa Y, Takahashi T, Kobayashi T, et al: Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation is converted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as a new radiosensitizer. Int J Mol Med. 12:845–850. 2003.
3	Ogawa Y, Takahashi T, Kobayashi T, et al: Immunocytochemical characteristics of human osteosarcoma cell line HS-Os-1: possible implication in apoptotic resistance against irradiation. Int J Mol Med. 14:397–403. 2004.
4	Kariya S, Sawada K, Kobayashi T, et al: Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells. Int J Radiat Oncol Biol Phys. 75:449–454. 2009.
5	Ogawa Y, Ue H, Tsuzuki K, et al: New radiosensitization treatment (KORTUC I) using hydrogen peroxide solution-soaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 19:1389–1394. 2008.
6	Ogawa Y, Kubota K, Ue H, et al: Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 34:609–618. 2009.
7	Miyatake K, Kubota K, Ogawa Y, et al: Non-surgical care for locally advanced breast cancer: radiologically assessed therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy. Oncol Rep. 24:1161–1168. 2010.
8	Ogawa Y, Kubota K, Ue H, et al: Safety and effectiveness of a new enzyme-targeting radiosensitization treatment (KORTUC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 39:553–560. 2011.
9	Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
10	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008.
11	Philip PA, Mooney M, Jaffe D, et al: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 27:5660–5669. 2009.
12	Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.
13	Yamaguchi K, Nakamura K, Kobayashi K, et al: ERT following IORT improves survival of patients with respectable pancreatic cancer. Hepatogastroenterology. 52:1244–1249. 2005.
14	Ruano-Ravina A, Almazán Ortega R and Guedea F: Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol. 87:318–325. 2008.
15	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996.
16	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
17	Jette DC, Wiebe LI and Chapman JD: Synthesis and in vivo studies of the radiosensitizer 4-[82Br]bromomisonidazole. Int J Nucl Med Biol. 10:205–210. 1983.
18	Coleman CN: Hypoxic cell radiosensitizers: expectations and progress in drug development. Int J Radiat Oncol Biol Phys. 11:323–329. 1985.
19	Hall EJ: Oxygen effect and reoxygenation. Radiobiology for the Radiologist. Hall EJ: 5th edition. J.B. Lippincott Co; Philadelphia, PA: pp. 91–111. 2000
20	Lawrence TS, Blackstock AW and McGinn C: The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 13:13–21. 2003.
21	Choy H and Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst. 95:1440–1452. 2003.
22	Overgaad J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 6:509–518. 1994.
23	O’Connor JK, Sause WT, Hazard LJ, et al: Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampllary adenocarcinoma. Int J Radiat Oncol Biol Phys. 63:1060–1066. 2005.
24	Ma HB, Di ZL, Wang XJ, et al: Effect of intraoperative radiotherapy combined with external beam radiotherapy following internal drainage for advanced pancreatic cancer. World J Gastroenterol. 10:1669–1771. 2004.
25	Furuse J, Kinoshita T, Kawashima M, et al: Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer. 97:1346–1352. 2003.
26	Ogawa K, Karasawa K, Ito Y, et al; JROSG Working Subgroup of Gastrointestinal Cancers. Intraoperative radiotherapy for unresectable pancreatic cancer: a multi-institutional retrospective analysis of 144 patients. Int J Radiat Oncol Biol Phys. 80:111–118. 2011.
27	Sunamura M, Karasawa K, Okamoto A, et al; PR-350 study group. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas. 28:330–334. 2004.